RNS Number : 1231M
N4 Pharma PLC
26 April 2024

N4 Pharma plc
("N4 Pharma" or the "Company")

N4 Pharma Webinar on SRI Collaboration

N4 Pharma Plc (AIM: N4P), the specialist pharmaceutical company developing Nuvec®, a novel delivery system for cancer treatments and vaccines, will provide a pre-recorded webinar relating to the Company's recent Collaboration Agreement with SRI International Inc. which was announced on 25 April 2024.

The webinar will be available for viewing on 7 May 2024 at 10:00 BST, via the Company's Investor Hub: investors.n4pharma.com/welcome.

Investors will be notified via email of the presentation if they have signed up to the N4 Pharma Investor Hub in advance, which can be done here: investors.n4pharma.com/auth/signup.

Investors are invited to submit questions in advance via N4 Pharma's Investor Hub, and CEO Nigel Theobald will address as many as possible. Register and submit questions at: investors.n4pharma.com

For more information please contact:

N4 Pharma plc Nigel Theobald, CEO Luke Cairns, Executive Director	investors.n4pharma.com
SP Angel Corporate Finance LLP *Nominated Adviser and Joint Broker* Matthew Johnson/Caroline Rowe/Kasia Brzozowska (Corporate Finance) Vadim Alexandre/Abigail Wayne/Rob Rees (Corporate Broking)	Tel: +44(0)20 3470 0470
InvestorHub Engage with us directly at N4 Pharma Investor Hub	Sign up at investors.n4pharma.com https://investors.n4pharma.com/link/4PKgJP

About N4 Pharma
N4 Pharma is a specialist pharmaceutical company developing a novel delivery system for oncology, gene therapy and vaccines using its unique silica nanoparticle delivery system called Nuvec®.

N4 Pharma's business model is to partner with companies developing novel antigens in these fields to use Nuvec® as the delivery vehicle for these antigens. As these products progress through pre clinical and clinical programs, N4 Pharma will seek to receive upfront payments, milestone payments and ultimately royalty payments once products reach the market.

For further information on the Company visit www.n4pharma.com or sign up at www.investors.n4pharma.com.

This information is provided by Reach, the non-regulatory press release distribution service of RNS, part of the London Stock Exchange. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

NRAUVAURSAUSUUR